Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New York EPIC Rx Plan Will Wrap Around Part D; Model For Other States?

Executive Summary

New York plans to retain its state pharmaceutical assistance program once the Medicare Part D drug benefit goes into effect, EPIC Director Julie Naglieri said during the NACDS Medicare Prescription Drugs & Reform conference in Baltimore March 3

You may also be interested in...

State Rx Programs May Not Steer Patients To Preferred Medicare Plan – CMS

State pharmaceutical assistance programs may not steer Medicare beneficiaries into preferred Part D drug plans, the final Medicare rule states

CMS Finalizes Medicare Rx Regs; Rebate Rules Await Further Guidance

The Centers for Medicare & Medicaid Services will issue a guidance on how Part D plan sponsors should report rebates following the publication of the final implementing regulations

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts